Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion.
Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a partner of Gilead before takeover talks began.
Terms are expected to be announced Monday.
Immunomedics, whose valuation hovers $10 billion, is just the latest in a series of deals Gilead made in 2020.
In June, Foster City, California-based Gilead acquired a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics for $275 million. Before that, it spent $4.9 billion for Forty Seven Inc., a company that makes blood cancer treatments.
Gilead closed Friday, Sept. 11 at $65.58 a share, while Immunomedics shares closed at $41.93.
See more from Benzinga
- SoftBank Close To Selling Chip Designer To Nvidia For B
- CBD Saved This Exec's Life: Now He's Launching His Own 'Connoisseur Cannabis' Brand
- Amyris Denies 'Patent Infringement' Allegations On Heels Of 1M Lavvan Lawsuit
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Business - Latest - Google News
September 13, 2020 at 05:22AM
https://ift.tt/3irpdk1
Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal - Yahoo Finance
Business - Latest - Google News
https://ift.tt/2Rx7A4Y
Bagikan Berita Ini
0 Response to "Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal - Yahoo Finance"
Post a Comment